Dantrolene inhibition of the hepatic mixed function oxidase system.
The effect of dantrolene sodium, a skeletal muscle relaxant, on the hepatic MFO system has been investigated. The dantrolene produces a dose related inhibition of the system. Single doses of 100 mg/kg and accumulative doses up to 125 mg/kg prolong pentobarbital sleeping time and decrease the rate of aminopyrine N-demethylation without altering cytochrome P450 content. However, single doses of 400 mg/kg and accumulative doses of 500 mg/kg do cause a decrease in cytochrome P450 content as part of the dantrolene induced inhibition of the hepatic MFO system.
D000633:Aminopyrine N-Demethylase / Q000378:metabolism; D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003620:Dantrolene / Q000494:pharmacology*; D005037:Ethylmorphine-N-Demethylase / Q000378:metabolism; D006591:Hexobarbital / Q000378:metabolism; D006827:Hydantoins / Q000494:pharmacology*; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D008748:Methylcholanthrene / Q000494:pharmacology; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010634:Phenobarbital / Q000494:pharmacology; D051381:Rats; D013997:Time Factors
D006827:Hydantoins; D008748:Methylcholanthrene; D003577:Cytochrome P-450 Enzyme System; D006591:Hexobarbital; D006899:Mixed Function Oxygenases; D010088:Oxidoreductases; D000633:Aminopyrine N-Demethylase; D005037:Ethylmorphine-N-Demethylase; D003620:Dantrolene; D010634:Phenobarbital